New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
10:55 EDTACAD, ACAD, ATTU, ATTU, CODE, CODE, AERI, AERI, EGAN, EGAN, IMAX, IMAX, SPNS, SPNS, JAKK, JAKK, CNAT, CNAT, BIRT, BIRT, BDSI, BDSI, PERI, PERIRoth Capital to hold a conference
26th Annual Growth Stock Conference is being held in Dana Point, California on March 9-12 with webcasted company presentations to begin on March 10 at 11 am; not all company presentations may be webcasted. Webcast Link
News For ACAD;BDSI;BIRT;CNAT;JAKK;SPNS;IMAX;EGAN;AERI;CODE;ATTU;PERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
08:13 EDTSPNSSapiens management to meet with Roth Capital
Meetings to be held in Los Angeles on July 7 and in San Francisco on July 8 hosted by Roth Capital.
07:33 EDTIMAXIMAX optioned several theatrical rights
Subscribe for More Information
June 29, 2015
07:56 EDTIMAXIMAX estimates raised above consensus at B. Riley
Subscribe for More Information
June 26, 2015
12:27 EDTCODECypress Semiconductor could rise 30%, Barron's says
Subscribe for More Information
10:14 EDTACADOptions with decreasing implied volatility
Subscribe for More Information
08:54 EDTSPNSSapiens price target raised to $12 from $10 at Roth Capital
Subscribe for More Information
June 25, 2015
07:09 EDTCNATConatus announces initial baseline data from Phase 2b POLT-HCV-SVR trial
Conatus announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company's Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant, or POLT, recipients. These patients have reestablished liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus, or HCV, infection and have successfully achieved a sustained viral response, or SVR, following HCV antiviral therapy, or POLT-HCV-SVR. Among the first 16 patients enrolled, more than 85% achieved SVRs using recently approved oral HCV antiviral treatments. The excitement generated by these new treatments altered enrollment patterns during the early stage of the POLT-HCV-SVR trial, and their rapid market penetration is now expanding the trial-eligible population. The double-blind, placebo-controlled trial was initiated in May 2014 in patients with Ishak Fibrosis Scores of 2 to 4. Consistent with the company's initial registration focus on the development of a treatment for cirrhosis, the trial was expanded in early 2015 to include patients with Ishak 5 and is currently expanding to Ishak 6. Patients are being randomized 2:1 to receive either 25 mg of emricasan or placebo orally twice daily for 24 months and will be followed for another month post-treatment. The primary endpoint in this exploratory proof-of-concept trial is the change in the Ishak Fibrosis Score compared with placebo. The trial will also evaluate histological markers of inflammation, key serum biomarkers, and the safety and tolerability of emricasan in the target patient population. Enrollment of approximately 60 total planned patients is on track for release of final top-line results in the first half of 2018.
June 24, 2015
07:31 EDTIMAXIMAX signs first agreement in Nigeria with Filmhouse Cinemas
Subscribe for More Information
June 22, 2015
17:16 EDTAERITPG Group lowers stake in Aerie Pharmaceuticals to 4.9% from 7.6%
June 19, 2015
10:00 EDTAERIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aerie Pharmaceuticals (AERI) upgraded to Buy from Hold at Canaccord... Amedisys (AMED) upgraded to Buy from Hold at Jefferies... Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI... Delta Air Lines (DAL) upgraded to Outperform from Peer Perform at Wolfe Research... Deutsche Bank (DB) upgraded to Neutral from Underperform at Exane BNP Paribas... EP Energy (EPE) upgraded on better than expected well economics at SunTrust... Encana (ECA) upgraded to Outperform from Market Perform at BMO Capital... Energy Transfer Partners (ETP) upgraded to Buy at BofA/Merrill... Erickson (EAC) upgraded to Outperform from In-Line at Imperial Capital... Fiserv (FISV) upgraded on growth opportunities, margin outlook at Oppenheimer... IPC Healthcare (IPCM) upgraded to Buy from Hold at Jefferies... Mack-Cali Realty (CLI) upgraded on valuation at Stifel... Micron (MU) upgraded to Buy on sustainable margins and capex at Topeka... NuStar Energy (NS) upgraded to Buy from Neutral at BofA/Merrill... NuStar GP Holdings (NSH) upgraded to Buy from Neutral at BofA/Merrill... Ramco-Gershenson (RPT) upgraded to Outperform from Neutral at Baird... Retail Opportunity (ROIC) upgraded to Outperform from Market Perform at Raymond James... Royal Dutch Shell (RDS.A) upgraded to Outperform from Sector Perform at RBC Capital... Smith & Wesson (SWHC) upgraded to Outperform from Sector Perform at RBC Capital... Sovran Self Storage (SSS) upgraded to Buy from Hold at Cantor... Springleaf (LEAF) upgraded to Outperform from Neutral at Macquarie.
09:18 EDTAERIOn The Fly: Pre-market Movers
Subscribe for More Information
08:25 EDTAERIAerie Pharmaceuticals upgraded to Buy, target raised to $40 at Canaccord
Subscribe for More Information
06:50 EDTAERIAerie Pharmaceuticals upgraded to Buy from Hold at Canaccord
Subscribe for More Information
June 18, 2015
12:04 EDTJAKKJAKKS Pacific management to meet with Piper Jaffray
Subscribe for More Information
05:31 EDTIMAXAMC Entertainment upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
June 17, 2015
20:03 EDTIMAXIMAX launches private theatre 'Palais' in China
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use